Clinical Trial For Lung Cancer
March 5th, 2010
No comments
Synta Presents STA-9090 NSCLC Data At The IASLC 10th Annual Targeted Therapies Of The Treatment Of Lung Cancer Meeting
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Dr. Geoffrey I. Shapiro of Dana-Farber Cancer Institute, presented preclinical and clinical data on STA-9090, a potent second-generation Hsp90 inhibitor, at IASLC (International Association …
Stories of Strength: Making the Decision to Enter a Lung Cancer Clinical Trial (Part 1 of 3)
